Table 4.
Differences in patients’ management of exacerbations between groups. Values are numbers (percentages) unless stated otherwise
| Exacerbation management | Self management (SM) (n=53) | Routine monitoring (RM) (n=55) | Usual care (UC) (n=48) | Odds ratio (95% CI)* | |
|---|---|---|---|---|---|
| SM v UC | RM v UC | ||||
| Baseline to 12 months: | (n=150)† | (n=179)† | (n=131)† | ||
| Increased bronchodilator | 65 (43) | 65 (36) | 40 (31) | 1.70 (0.81 to 3.54) | 1.22 (0.60 to 2.48) |
| Prednisolone and/or antibiotics | 16 (11) | 22 (12) | 13 (10) | 1.24 (0.43 to 3.57) | 1.28 (0.57 to 2.87) |
| Unscheduled medical contact | 20 (13) | 27 (15) | 18 (14) | 1.09 (0.42 to 2.81) | 1.08 (0.52 to 2.23) |
| 12-24 months: | (n=130)† | (n=131)† | (n=104)† | ||
| Increased bronchodilator | 60 (46) | 56 (43) | 28 (27) | 2.81 (1.16 to 6.82) | 2.17 (0.95 to 4.95) |
| Prednisolone and/or antibiotics | 20 (15) | 9 (7) | 5 (5) | 3.98 (1.10 to 15.58) | 1.71 (0.44 to 5.94) |
| Unscheduled medical contact | 24 (18) | 12 (9) | 12 (12) | 2.07 (0.60 to 7.15) | 0.93 (0.30 to 2.95) |
*Estimated by using generalised estimating equations logistic regression models with compound symmetry with sex, age, educational level, long acting bronchodilator use, and inhaled corticosteroid use as covariates.
†Number of exacerbations.